A Study of DM005 in Patients With Advanced Solid Tumors
Description
This first-in-human (FIH), multicenter, open-label, dose escalation and dose expansion study is to evaluate the safety, preliminary efficacy and pharmacokinetic (PK) characteristics of DM005 monotherapy in participants with advanced solid tumors.
DM005, a bispecific ADC developed using fully human antibodies with a common light chain, which targets c-MET and EGFR.
Subjects with solid malignant tumors will be treated with DM005 on Day 1 once Q3W (dose adjustments may be required depending on the safety profile and PK data of each dose
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites